CARMEL, Ind. — February 11, 2026 — Leads & Copy —
MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company, announced that President and CEO Kent Hawryluk and Chief Medical Officer Sam Azoulay, M.D., will present at upcoming investor conferences.
Hawryluk and Azoulay will participate in a fireside chat and 1×1 meetings at the 36th Oppenheimer Annual Healthcare Life Sciences Conference (Virtual) on Wednesday, February 25, 2026, from 11:20 a.m. – 11:50 a.m. ET.
They will also participate in a fireside chat and 1×1 meetings at the TD Cowen 46th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 2, 2026, from 9:10 a.m. – 9:40 a.m. ET.
Live webcasts can be accessed in the events section of the MBX Biosciences website. Webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
MBX Biosciences is focused on novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.
The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) preparing for Phase 3 development; an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates; and imapextide (MBX 1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development. The Company is based in Carmel, Indiana.
Source: MBX Biosciences
